Manufacturing

Medical Devices
Regulatory Science

Globus Medical wins CE Mark for Excelsius3D imaging system in EU and UK

The Pennsylvania-based medtech said the CE Mark opens European commercial sales of its intraoperative 3-in-1 imaging platform, which integrates with its ExcelsiusGPS
The Pennsylvania-based medtech said the CE Mark opens European commercial sales of its intraoperative 3-in-1 imaging platform, which integrates with its ExcelsiusGPS
Bioprocessing
Regulatory Science

TOMI Environmental gains Ireland BPR approval for SteraMist

TOMI Environmental's iHP decontamination technology is now authorised in Ireland, bringing its EU market approvals to 11 countries.
TOMI Environmental's iHP decontamination technology is now authorised in Ireland, bringing its EU market approvals to 11 countries.
Biologics
Diagnostics

IBA swings to profit in H1 2026 as proton therapy orders surge

The Belgian particle accelerator group posted a €9.3m net profit in H1 2026, reversing a prior-year loss, with proton therapy order intake more
The Belgian particle accelerator group posted a €9.3m net profit in H1 2026, reversing a prior-year loss, with proton therapy order intake more
Diagnostics

Vivos Inc. ships first IsoPet batches from in-house US facility

Vivos has begun domestic IsoPet shipments from its Richland, WA site and secured Indian nuclear regulatory approval for a second international manufacturing centre.
Vivos has begun domestic IsoPet shipments from its Richland, WA site and secured Indian nuclear regulatory approval for a second international manufacturing centre.

Nuwellis signs co-promotion deal with Atrility for AtriAmp device

Nuwellis will co-promote Atrility's FDA-cleared cardiac pacing monitor across 14 US states, with an option to become exclusive national distributor.
Nuwellis will co-promote Atrility's FDA-cleared cardiac pacing monitor across 14 US states, with an option to become exclusive national distributor.
Diagnostics

Senseonics raises CGM revenue guidance after 120% Q2 growth

Senseonics lifted its full-year 2026 revenue target to $62–66 million after record quarterly revenue and gross margins beat its own guided range.
Senseonics lifted its full-year 2026 revenue target to $62–66 million after record quarterly revenue and gross margins beat its own guided range.
Biotech

Eos Energy posts 351% revenue jump but narrows 2026 guidance

The zinc-based storage company grew Q2 revenue to $68.8m but tightened its full-year outlook to $300m–$350m as manufacturing consolidation weighs on
The zinc-based storage company grew Q2 revenue to $68.8m but tightened its full-year outlook to $300m–$350m as manufacturing consolidation weighs on

LeMaitre Vascular posts 10% sales growth in Q2 2026

The Burlington-based vascular device maker reported Q2 sales of $70.4m, with Artegraft up 34% as its international rollout accelerates across 56 countries.
The Burlington-based vascular device maker reported Q2 sales of $70.4m, with Artegraft up 34% as its international rollout accelerates across 56 countries.
Bioprocessing
Synthetic Biology

Capra Biosciences secures more HHS funding to onshore API output

Total ASPR backing reaches $17m as the Virginia biotech moves seven API targets toward commercial-scale domestic manufacturing.
Total ASPR backing reaches $17m as the Virginia biotech moves seven API targets toward commercial-scale domestic manufacturing.

Integra LifeSciences Q2 revenue steady as SurgiMend relaunch nears

Integra posted $418.8m in Q2 revenue and confirmed production at its Braintree facility, setting up a fourth-quarter SurgiMend relaunch.
Integra posted $418.8m in Q2 revenue and confirmed production at its Braintree facility, setting up a fourth-quarter SurgiMend relaunch.
Biologics

Anika Therapeutics raises 2026 guidance after record Q2 revenue

The Bedford, Massachusetts orthopaedics biotech posted record commercial channel revenue of $13.9m in Q2 2026 and lifted its full-year adjusted EBITDA margin outlook.
The Bedford, Massachusetts orthopaedics biotech posted record commercial channel revenue of $13.9m in Q2 2026 and lifted its full-year adjusted EBITDA margin outlook.
Bioprocessing
Biotech

ProLogium secures $50m PIPE ahead of SPAC listing on Nasdaq

The Taiwan-based solid-state battery maker has locked in $50m from existing shareholders to support its SPAC merger with TDAC and fund its French
The Taiwan-based solid-state battery maker has locked in $50m from existing shareholders to support its SPAC merger with TDAC and fund its French
Biologics

FDA approves Pluvicto for hormone-sensitive prostate cancer

Novartis wins approval to use its radioligand therapy earlier in metastatic prostate cancer, nearly doubling the eligible patient population.
Novartis wins approval to use its radioligand therapy earlier in metastatic prostate cancer, nearly doubling the eligible patient population.
Biologics

Cellution Biologics acquires SimpliDerm ADM business for up to $11m

Cellution Biologics is buying Elutia's SimpliDerm acellular dermal matrix unit to enter the US reconstructive surgery market.
Cellution Biologics is buying Elutia's SimpliDerm acellular dermal matrix unit to enter the US reconstructive surgery market.
Digital Health

Kestra Medical secures $200m non-dilutive loan facility with Pharmakon

The Nasdaq-listed wearable cardiovascular device maker replaces a $45m term loan and unlocks up to $357m in total liquidity.
The Nasdaq-listed wearable cardiovascular device maker replaces a $45m term loan and unlocks up to $357m in total liquidity.
Biologics
Bioprocessing

VERAXA Biotech taps ATUM to develop cell lines for BiTAC-TCE programme

VERAXA has engaged ATUM's Leap-In Transposase technology to generate stable clonal cell lines for its lead conditional T-cell engager candidate ahead of
VERAXA has engaged ATUM's Leap-In Transposase technology to generate stable clonal cell lines for its lead conditional T-cell engager candidate ahead of
Biologics
Bioprocessing

Pluristyx secures Japan patent for synthetic mRNA iPSC reprogramming

The Seattle biotech's licensed mRNA technology cuts iPSC line generation to under 30 days, addressing a key bottleneck for commercial cell therapy manufacturing.
The Seattle biotech's licensed mRNA technology cuts iPSC line generation to under 30 days, addressing a key bottleneck for commercial cell therapy manufacturing.
Digital Health

CosmoFarm posts record $15m Q2 revenue on pharmacy network growth

The Athens-based pharmaceutical wholesaler added over 80 pharmacies in Q2 2026, lifting Cosmos Health's annualised revenue run-rate beyond $60 million.
The Athens-based pharmaceutical wholesaler added over 80 pharmacies in Q2 2026, lifting Cosmos Health's annualised revenue run-rate beyond $60 million.
Diagnostics
Biotech

Trinity Biotech wins 2m TrinScreen HIV order; Q1 revenue up 43%

Trinity Biotech secured orders for over 2 million TrinScreen HIV rapid tests, supporting 2026 targets as Q1 revenue rose 43% to $10.8m.
Trinity Biotech secured orders for over 2 million TrinScreen HIV rapid tests, supporting 2026 targets as Q1 revenue rose 43% to $10.8m.

Nyxoah draws $15m EIB tranche to fund US Genio launch

The Belgian sleep-apnea medtech has completed a $110m capital raise in June, combining equity proceeds with non-dilutive EIB debt financing.
The Belgian sleep-apnea medtech has completed a $110m capital raise in June, combining equity proceeds with non-dilutive EIB debt financing.
Subscribe to Manufacturing